GLP-1 receptor agonists were originally developed to lower blood sugar. What researchers discovered in subsequent cardiovascular outcome trials was something far more significant: these medications actively protect the heart, reduce the risk of stroke, and lower cardiovascular mortality — benefits that extend well beyond glucose control. The Landmark Cardiovascular Outcome Trials Trial Drug Key Finding…
Urdu 
English